TNFRSF9 and ovarian cancer: It is noteworthy, therefore, that peritoneal injection of anti-CD137 mAb, a procedure that can be applied clinically in patients with ovarian cancer, did not induce any obvious toxicity such as weight or hair loss either in this study or our preceding experiments in the ID8 model [27].